Sumitomo’s Patent Suit Win Over Latuda Antipsychotic Upheld

Sumitomo Dainippon Pharma Co.'s win in a suit claiming infringement of a patent covering its Latuda antipsychotic drug will stand.

The federal district court in New Jersey correctly construed a patent claim at issue in an infringement suit over the Latuda (lurasidone hydrochloride) patent, the U.S. Court of Appeals for the Federal Circuit ruled April 16. The construction of a compound chemical structure claim in U.S. Patent No. 5,532,372 in Sumitomo’s favor gave it a win in its fight to prevent generic competition to Latuda.

Latuda, produced by Sunovion and its U.S. subsidiary, Sunovion Pharmaceuticals Inc., treats schizophrenia and bipolar ...